ValiRx PLC - Director Disclosure
("ValiRx", the "Company" or the "Group")
This announcement is made in accordance with Rule 17 and schedule 2, paragraph (g) of the AIM Rules for Companies.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.
For further information please contact:
Tel: +44 (0) 2476 796496
Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0) 20 7213 0880
Peterhouse Capital Limited (Sole Broker)
Tel: +44 (0) 20 7469 0930
Optimum Strategic Communications
Tel: +44 (0) 20 8148 3040
About ValiRx plc
ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.
With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.
Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/
Quick facts: ValiRx PLC
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE